The effects of etomidate and midazolam on adipose tissue-derived mesenchymal stem cell proliferation.
Park H., Ryu K., Kim YH., Choi WJ., Ko D.
Prospective Study with a reported sample of 3, published in Korean J Anesthesiol (2016) — summary generated from the PubMed abstract.
Early human evidence such as case series or small samples is exploring possible benefits.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Prospective Study
- Journal
- Korean J Anesthesiol (2016)
- Country
- Korea (South)
- Reported sample size
- 3
- Source database
- PubMed
- PMID
- 27924203
- PMCID
- PMC5133234
- DOI
- 10.4097/kjae.2016.69.6.614
- Citations
- 1
Abstract (original English)
Background Stem cell therapy using adipose tissue-derived mesenchymal stem cells (ADSCs), which are capable of multipotent differentiation, is currently being investigated in the field of tissue regeneration and the treatment of patients in intensive care units. It is known that type-A γ-aminobutyric acid (GABA A ) receptor activity has an influence on stem cell proliferation. Thus, we investigated the effects of the clinically available GABA A receptor agonists, etomidate and midazolam, on ADSC proliferation measured by the cell counting kit-8 assay. Methods ADSCs cultured in control medium or adipogenic differentiation medium for 15 days were divided into 5 treatment groups: non-medicated (Control) and 4 groups including treatment with etomidate or midazolam at 1 and 50 µM (n = 3 per group). The cell counting kit-8 assay was performed for determining the cell proliferation in both medium groups at day 0, 3, 6, 9, 12, and 15 in culture. The absorbance values at 450 nm were then measured by enzyme-linked immunosorbent assay reader and statistically compared among groups. Results There was no significant difference in cell proliferation profiles among the 5 groups at any time point in both control and adipogenic differentiation media. Conclusions Etomidate and midazolam did not influence ADSC proliferation under both media when compared to the non-medicated group and there was n
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
Evidence level
Early human evidence such as case series or small samples is exploring possible benefits.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.